Overview Dividends

(VTYX) Ventyx Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92332V1070

Drug, Immune, Skin, Bowel, Psoriasis

VTYX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 44.30%
EPS Trend (3Y Correlation): 81.8%

VTYX Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 22.1%

Description: VTYX Ventyx Biosciences August 16, 2025

Ventyx Biosciences Inc (NASDAQ:VTYX) is a US-based pharmaceutical company. As a player in the pharmaceuticals industry, VTYX is subject to key economic drivers such as R&D pipeline progress, regulatory approvals, and market demand for its products.

The companys market capitalization stands at $200.38M USD, indicating a relatively small-cap stock with potential for significant price movements. The absence of a P/E ratio suggests that the company is currently unprofitable, which is common for biotech firms with promising pipelines but尚未 commercialized products.

To evaluate VTYXs performance, key performance indicators (KPIs) such as cash runway, R&D expenses as a percentage of market cap, and pipeline progress (e.g., number of assets in clinical trials, upcoming milestones) will be crucial. Investors should also monitor the companys burn rate and cash reserves to assess its ability to fund operations and achieve key milestones.

Given the industrys capital-intensive nature and the high-risk, high-reward profile of biotech investments, VTYXs stock price is likely to be influenced by news flow related to its pipeline, regulatory updates, and potential partnerships or collaborations. As such, investors should be prepared for potential volatility and closely monitor developments that could impact the companys valuation.

VTYX Stock Overview

Market Cap in USD	608m
Sub-Industry	Pharmaceuticals
IPO / Inception	2021-10-21

VTYX Stock Ratings

Growth Rating	-16.5%
Fundamental	36.7%
Dividend Rating	-
Return 12m vs S&P 500	247%
Analyst Rating	4.22 of 5

VTYX Dividends

Currently no dividends paid

VTYX Growth Ratios

Growth Correlation 3m	75.9%
Growth Correlation 12m	53.7%
Growth Correlation 5y	-68.5%
CAGR 5y	-28.27%
CAGR/Max DD 3y (Calmar Ratio)	-0.29
CAGR/Mean DD 3y (Pain Ratio)	-0.40
Sharpe Ratio 12m	-0.81
Alpha	298.33
Beta	1.011
Volatility	189.52%
Current Volume	3491.2k
Average Volume 20d	2485.9k
Stop Loss	8.3 (-7.8%)
Signal	-0.43

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-119.0m TTM) > 0 and > 6% of Revenue (6% = 86.9k TTM)

FCFTA -0.46 (>2.0%) and ΔFCFTA 5.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 14.4k% (prev 22.2k%; Δ -7841 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.46 (>3.0%) and CFO -105.7m > Net Income -119.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 19.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (71.2m) change vs 12m ago 0.91% (target <= -2.0% for YES)

Gross Margin 31.77% (prev -29.37%; Δ 61.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.54% (prev 0.35%; Δ 0.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -71.93 (EBITDA TTM -116.1m / Interest Expense TTM 1.63m) >= 6 (WARN >= 3)

Altman Z'' -36.60

(A) 0.90 = (Total Current Assets 219.3m - Total Current Liabilities 11.5m) / Total Assets 230.0m

(B) -2.65 = Retained Earnings (Balance) -608.7m / Total Assets 230.0m

warn (B) unusual magnitude: -2.65 — check mapping/units

(D) -29.50 = Book Value of Equity -608.5m / Total Liabilities 20.6m

Total Rating: -36.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.72

1. Piotroski 1.0pt = -4.0

2. FCF Yield -25.82% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.05 = 2.50

5. Debt/Ebitda 0.19 = 2.47

6. ROIC - WACC (= -48.13)% = -12.50

7. RoE -48.89% = -2.50

8. Rev. Trend 22.13% = 1.66

9. EPS Trend 81.75% = 4.09

What is the price of VTYX shares?

As of November 06, 2025, the stock is trading at USD 9.00 with a total of 3,491,171 shares traded.
Over the past week, the price has changed by +22.12%, over one month by +141.29%, over three months by +248.84% and over the past year by +312.84%.

Is Ventyx Biosciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Ventyx Biosciences (NASDAQ:VTYX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 36.72 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VTYX is around 8.66 USD . This means that VTYX is currently overvalued and has a potential downside of -3.78%.

Is VTYX a buy, sell or hold?

Ventyx Biosciences has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy VTYX.

Strong Buy: 5
Buy: 1
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the VTYX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	14.4	60%
Analysts Target Price	14.4	60%
ValueRay Target Price	9.8	8.8%

VTYX Fundamental Data Overview November 04, 2025

Market Cap USD = 608.3m (608.3m USD * 1.0 USD.USD)
P/B = 1.2022
Beta = 1.011
Revenue TTM = 1.45m USD
EBIT TTM = -117.4m USD
EBITDA TTM = -116.1m USD
Long Term Debt = 10.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.14m USD (from shortTermDebt, last quarter)
Debt = 10.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -22.0m USD (from netDebt column, last quarter)
Enterprise Value = 409.6m USD (608.3m + Debt 10.3m - CCE 209.0m)
Interest Coverage Ratio = -71.93 (Ebit TTM -117.4m / Interest Expense TTM 1.63m)
FCF Yield = -25.82% (FCF TTM -105.8m / Enterprise Value 409.6m)
FCF Margin = -7304 % (FCF TTM -105.8m / Revenue TTM 1.45m)
Net Margin = -8220 % (Net Income TTM -119.0m / Revenue TTM 1.45m)
Gross Margin = 31.77% ((Revenue TTM 1.45m - Cost of Revenue TTM 988.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.78 (Enterprise Value 409.6m / Total Assets 230.0m)
Interest Expense / Debt = 35.17% (Interest Expense 3.62m / Debt 10.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -92.7m (EBIT -117.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.12 (Total Current Assets 219.3m / Total Current Liabilities 11.5m)
Debt / Equity = 0.05 (Debt 10.3m / totalStockholderEquity, last quarter 209.4m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -22.0m / EBITDA -116.1m)
Debt / FCF = 0.21 (negative FCF - burning cash) (Net Debt -22.0m / FCF TTM -105.8m)
Total Stockholder Equity = 243.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.75% (Net Income -119.0m / Total Assets 230.0m)
RoE = -48.89% (Net Income TTM -119.0m / Total Stockholder Equity 243.5m)
RoCE = -46.26% (EBIT -117.4m / Capital Employed (Equity 243.5m + L.T.Debt 10.3m))
RoIC = -38.09% (negative operating profit) (NOPAT -92.7m / Invested Capital 243.5m)
WACC = 10.04% (E(608.3m)/V(618.6m) * Re(9.74%) + D(10.3m)/V(618.6m) * Rd(35.17%) * (1-Tc(0.21)))
Discount Rate = 9.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.78%
Fair Price DCF = unknown (Cash Flow -105.8m)
EPS Correlation: 81.75 | EPS CAGR: 44.30% | SUE: 4.0 | # QB: 1
Revenue Correlation: 22.13 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for VTYX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle